A Phase I clinical trial of AFM13 for the treatment of relapsed/refractory CD30-positive Hodgkin lymphoma has been completed, and results were presented at the American Association for Cancer Research 2021 Annual Meeting, demonstrating that AFM13 treats relapsed/refractory CD30-positive Hodgkin lymphoma The objective response rate of the tumor was 100%. Here, TNFRSF8 is linked to Hodgkins lymphoma.